A
Alexandre V. Hirayama
Researcher at Fred Hutchinson Cancer Research Center
Publications - 46
Citations - 1986
Alexandre V. Hirayama is an academic researcher from Fred Hutchinson Cancer Research Center. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 11, co-authored 33 publications receiving 1005 citations.
Papers
More filters
Journal ArticleDOI
Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes.
Daniel E. Leisman,Daniel E. Leisman,Daniel E. Leisman,Lukas Ronner,Lukas Ronner,Rachel Pinotti,Matthew D. Taylor,Matthew D. Taylor,Pratik Sinha,Carolyn S. Calfee,Alexandre V. Hirayama,Fiore Mastroiani,Cameron J. Turtle,Michael O. Harhay,Matthieu Legrand,Clifford S. Deutschman,Clifford S. Deutschman +16 more
TL;DR: The findings question the role of a cytokine storm in COVID-19-induced organ dysfunction and the potential role of anti-cytokine and immune-modulating treatments in patients with the disease.
Journal ArticleDOI
Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy.
Kevin A. Hay,Kevin A. Hay,Jordan Gauthier,Alexandre V. Hirayama,Jenna M. Voutsinas,Qian Wu,Daniel Li,Ted Gooley,Sindhu Cherian,Xueyan Chen,Barbara S. Pender,Reed M. Hawkins,Aesha Vakil,Rachel N. Steinmetz,Gary Schoch,Aude G. Chapuis,Aude G. Chapuis,Brian G. Till,Brian G. Till,Hans-Peter Kiem,Hans-Peter Kiem,Jorge Ramos,Jorge Ramos,Mazyar Shadman,Mazyar Shadman,Ryan D. Cassaday,Ryan D. Cassaday,Utkarsh Acharya,Utkarsh Acharya,Stanley R. Riddell,Stanley R. Riddell,David G. Maloney,David G. Maloney,Cameron J. Turtle,Cameron J. Turtle +34 more
TL;DR: Patients with relapsed/refractory B-ALL enrolled in a phase 1/2 clinical trial evaluating lymphodepletion chemotherapy followed by CD19 CAR T-cell therapy who might benefit from consolidation strategies such as allogeneic HCT are studied.
Journal ArticleDOI
The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells.
Alexandre V. Hirayama,Jordan Gauthier,Kevin A. Hay,Kevin A. Hay,Jenna M. Voutsinas,Qian Wu,Ted Gooley,Daniel Li,Sindhu Cherian,Xueyan Chen,Barbara S. Pender,Reed M. Hawkins,Aesha Vakil,Rachel N. Steinmetz,Utkarsh Acharya,Utkarsh Acharya,Ryan D. Cassaday,Ryan D. Cassaday,Aude G. Chapuis,Aude G. Chapuis,Tejaswini Dhawale,Paul C. Hendrie,Hans-Peter Kiem,Hans-Peter Kiem,Ryan C. Lynch,Ryan C. Lynch,J L Ramos,J L Ramos,Mazyar Shadman,Mazyar Shadman,Brian G. Till,Brian G. Till,Stanley R. Riddell,Stanley R. Riddell,David G. Maloney,David G. Maloney,Cameron J. Turtle,Cameron J. Turtle +37 more
TL;DR: Analysis of clinical and treatment characteristics, serum biomarkers, and CAR T-cell manufacturing and pharmacokinetic data showed that a lower pre-lymphodepletion serum lactate dehydrogenase (LDH) level and a favorable cytokine profile, defined as serum day 0 monocyte chemoattractant protein-1 (MCP-1) and peak interleukin-7 (IL-7) concentrations above the median, were associated with better PFS.
Journal ArticleDOI
Feasibility and efficacy of CD19-targeted CAR-T cells with concurrent ibrutinib for CLL after ibrutinib failure.
Jordan Gauthier,Jordan Gauthier,Alexandre V. Hirayama,Janaki Purushe,Kevin A. Hay,Kevin A. Hay,James Lymp,Daniel H. Li,Cecilia C. S. Yeung,Cecilia C. S. Yeung,Alyssa Sheih,Barbara S. Pender,Reed M. Hawkins,Aesha Vakil,Tinh-Doan Phi,Rachel N. Steinmetz,Mazyar Shadman,Mazyar Shadman,Stanley R. Riddell,Stanley R. Riddell,David G. Maloney,David G. Maloney,Cameron J. Turtle,Cameron J. Turtle +23 more
TL;DR: CD19 CAR-T cell immunotherapy with concurrent ibrutinib for R/R CLL were well tolerated, with low CRS severity, and led to high rates of MRD-negative response by IGH sequencing.
Journal ArticleDOI
Late Events after Treatment with CD19-Targeted Chimeric Antigen Receptor Modified T Cells
Ana Cordeiro,Evandro D. Bezerra,Alexandre V. Hirayama,Joshua A. Hill,Joshua A. Hill,Qian Wu,Jenna M. Voutsinas,Mohamed L. Sorror,Mohamed L. Sorror,Cameron J. Turtle,Cameron J. Turtle,David G. Maloney,David G. Maloney,Merav Bar,Merav Bar +14 more
TL;DR: Most of the late events observed in this cohort were not severe and many could be related to prior or subsequent therapies, suggesting a safe long-term profile of CD19-targeted CAR-T cell immunotherapy.